Key result
Aortic homograft resolves prosthetic valve endocarditis and preserves function without lifelong anticoagulation in pediatric redo.
Why the study?
Management of prosthetic aortic valve endocarditis with severe prosthesis-patient mismatch and active infection in pediatric patients requires effective surgical strategies.
Case Report (n=1)
A cryopreserved composite aortic homograft was effectively used in a pediatric patient to treat active prosthetic aortic valve endocarditis while avoiding lifelong anticoagulation.
Answers are grounded in this paper and cite their sources.
Supports homograft in pediatric prosthetic endocarditis to avoid anticoagulation; leaves open prospective validation before wider use.
A composite aortic homograft was used in a 14-year-old patient with prosthetic aortic valve endocarditis. There were severe prosthesis-patient mismatch and active infection confirmed by Staphylococcus aureus isolation. Redo surgery implied removal of infected prosthesis, debridement and implantation of a cryopreserved composite homograft. Postoperative period was characterized by normal homograft function, relief of infection and significant clinical improvement without the need for lifelong anticoagulation. Homograft demonstrated high efficacy in complex clinical scenario.
No takes yet. Share an insight, caveat, or question.
Komarov et al. (2026) conducted a case report in Prosthetic aortic valve endocarditis (n=1). Composite aortic homograft was evaluated on Clinical outcome (homograft function, relief of infection). Implantation of a composite aortic homograft in a 14-year-old with prosthetic aortic valve endocarditis provided normal homograft function and relief of infection without lifelong anticoagulation.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: